Olgun Küçük Hilal, Küçük Uğur, Demirtaş Canan, Özdemir Murat
Department of Cardiolgy, Siyami Ersek Thoracic and Cardiovascular Surgery Center Training and Research Hospital İstanbul 34668, Turkey.
Department of Cardiology, Gulhane Military Medical Academy Haydarpasa Training Hospital İstanbul 34668, Turkey.
Int J Clin Exp Med. 2015 Dec 15;8(12):22543-9. eCollection 2015.
BACKGROUND: Clinical and epidemiological data well defines the role of atherosclerotic risk factors in pathogenesis of aortic stenosis. Especially dyslipidemia with elevated total and LDL cholesterol levels exerts certain histopathological changes on calcified valve tissue. Exact role of HDL in this process is not known. OBJECTIVE: To evaluate the lipid profiles of patients with mild aortic valve stenosis with special focus on HDL; HDL subspecies, serum apoA1 levels, HDL related PON1 and PAF-AH enzyme activities and to correlate this with disease progression rates. METHOD: 42 patients (26 female; 16 male), with calcific aortic valve stenosis were enrolled in the study. Serum fasting lipid parameters, HDL subspecies (HDL2, HDL3), serum apoA1 levels and HDL related PON1 and PAF-AH enzyme activities were determined. All participants underwent detailed follow-up transthoracic echocardiography examination. RESULTS: Among 42 study participants mean serum total cholesterol level was 195 ± 27.3 mg/dl, LDL-c level was 123 ± 19.1 mg/dl, HDL-c level was 44 ± 10.3 mg/dl and total cholesterol/HDL-c ratio was 4.64 ± 1.13. Basal peak aortic jet velocity (Vmax2) was 2.67 ± 0.39 m/sec, mean pressure gradient (Pmean2) was 15.6 ± 5.5 mmhg. Annual progression rate in peak aortic jet velocity (Vmax) was 0.23 ± 0.17 m/sec, in mean pressure gradient (Pmean) was 3 ± 2.1 mmhg. Annual progression rate in Pmean was most strongly correlated with serum HDL-c level and total/HDL-c ratio (r=-0.528 and 0.505; <0.001 and 0.001 respectively). Progression in Vmax values was positively correlated with serum LDL-c level and total/HDL-c ratio while negatively correlated with serum HDL-c levels (r=0.328, 0.499 and -0.464; P=0.034, 0.001 and 0.002 respectively). Among HDL subspecies HDL2 was the predominant type. HDL2 levels were found to be positively correlated with progression rates. There was no significant correlation between apolipoprotein A1 level and annual progression rate. Serum PON1 activity level was determined to be negatively correlated to doppler echocardiographic progression parameters while HDL related PAF-AH activity was independent of disease progression. CONCLUSION: Present study demonstrated a positive correlation between disease progression and serum total cholesterol/HDL-c ratio. Serum HDL-c level was inversely correlated with hemodynamic progression. The majority of HDL was HDL2 subtype. Among HDL related enzymes PON1 enzyme activity exhibited an inverse correlation with disease progression.
背景:临床和流行病学数据明确了动脉粥样硬化危险因素在主动脉瓣狭窄发病机制中的作用。尤其是总胆固醇和低密度脂蛋白胆固醇水平升高的血脂异常会对钙化瓣膜组织产生某些组织病理学变化。高密度脂蛋白在这一过程中的具体作用尚不清楚。 目的:评估轻度主动脉瓣狭窄患者的血脂谱,特别关注高密度脂蛋白;高密度脂蛋白亚类、血清载脂蛋白A1水平、与高密度脂蛋白相关的对氧磷酶1(PON1)和血小板活化因子乙酰水解酶(PAF-AH)的酶活性,并将其与疾病进展率相关联。 方法:42例钙化性主动脉瓣狭窄患者(26例女性;16例男性)纳入本研究。测定血清空腹血脂参数、高密度脂蛋白亚类(HDL2、HDL3)、血清载脂蛋白A1水平以及与高密度脂蛋白相关的PON1和PAF-AH酶活性。所有参与者均接受详细的经胸超声心动图随访检查。 结果:42例研究参与者中,血清总胆固醇水平平均为195±27.3mg/dl,低密度脂蛋白胆固醇水平为123±19.1mg/dl,高密度脂蛋白胆固醇水平为44±10.3mg/dl,总胆固醇/高密度脂蛋白胆固醇比值为4.64±1.13。基础主动脉峰值流速(Vmax2)为2.67±0.39m/秒,平均压力阶差(Pmean2)为15.6±5.5mmHg。主动脉峰值流速(Vmax)的年进展率为0.23±0.17m/秒,平均压力阶差(Pmean)的年进展率为3±2.1mmHg。Pmean的年进展率与血清高密度脂蛋白胆固醇水平和总胆固醇/高密度脂蛋白胆固醇比值相关性最强(r分别为-0.528和0.505;P均<0.001)。Vmax值的进展与血清低密度脂蛋白胆固醇水平和总胆固醇/高密度脂蛋白胆固醇比值呈正相关,而与血清高密度脂蛋白胆固醇水平呈负相关(r分别为0.328、0.499和-0.464;P分别为0.034、0.001和0.002)。在高密度脂蛋白亚类中,HDL2是主要类型。发现HDL2水平与进展率呈正相关。载脂蛋白A1水平与年进展率之间无显著相关性。血清PON1活性水平与多普勒超声心动图进展参数呈负相关,而与高密度脂蛋白相关的PAF-AH活性与疾病进展无关。 结论:本研究表明疾病进展与血清总胆固醇/高密度脂蛋白胆固醇比值呈正相关。血清高密度脂蛋白胆固醇水平与血流动力学进展呈负相关。大多数高密度脂蛋白为HDL2亚型。在与高密度脂蛋白相关的酶中,PON1酶活性与疾病进展呈负相关。
Int J Clin Exp Med. 2015-12-15
Front Cardiovasc Med. 2023-7-17
Clin Chim Acta. 2013-11-23
CJC Open. 2024-6-11
Medicina (Kaunas). 2019-7-29
Medicina (Kaunas). 2018-4-25
Med J Armed Forces India. 2018-1
Arterioscler Thromb Vasc Biol. 2013-12-12
J Heart Valve Dis. 2010-7
Circulation. 2009-5-26
Biofactors. 2009